GoodRx HoldingsGDRX -2.18%60 EBITDA Margin % is 19.17% as of Mar. 2026, which is 13% above its 10-year median of 16.97. GuruFocus rates GDRX with a GF Score™ of 60/100 and a GF Value™ of $5.66 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, GoodRx Holdings ranks better than 80.09% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. GoodRx Holdings's EBITDA for the
three
months ended in Mar. 2026 was $37.2 Mil. GoodRx Holdings's Revenue for the
three
months ended in Mar. 2026 was $194.0 Mil. Therefore, GoodRx Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 19.17%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GoodRx Holdings EBITDA Margin % Related Terms
GoodRx Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for GoodRx Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GDRX vs OMDA, CERT, TALK: EBITDA Margin % Comparison
For the Health Information Services subindustry, GoodRx Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GoodRx Holdings EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, GoodRx Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GoodRx Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GoodRx Holdings (GDRX) has a EBITDA Margin % of 19.17% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GoodRx Holdings and its competitors. This is 13% above median its historical median of 16.97. According to the industry distribution chart, GoodRx Holdings ranks #133 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 19.9%.
Is GoodRx Holdings' EBITDA Margin % too high?
GoodRx Holdings' current EBITDA Margin % of 19.17% is 13% above median its 10-year median of 16.97. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. GoodRx Holdings' value of 19.17% is 87.8% above this industry median. Based on the distribution chart, GoodRx Holdings ranks #133 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, GoodRx Holdings has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GoodRx Holdings' EBITDA Margin % compare to OMDA and CERT?
According to the Healthcare Providers & Services industry distribution chart, GoodRx Holdings ranks #133 out of 668 companies for EBITDA Margin %. This places GoodRx Holdings in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. GoodRx Holdings' value of 19.17% is 87.8% above this benchmark. While the company's 10-year median is 16.97 vs. the industry median of 10.21, GoodRx Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GoodRx Holdings's current EBITDA Margin % of 19.17% is 87.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GoodRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GoodRx Holdings's current EBITDA Margin % is 19.17%, which is 13% above median its own 10-year median of 16.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GoodRx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GoodRx Holdings (GDRX) is currently considered Possible Value Trap. The stock's GF Value™ is $5.66, compared to a current price of $2.69 — trading 52.5% below its estimated fair value. The current EBITDA Margin % is 19.17%, which is 13% above median its 10-year median of 16.97 and 87.8% above the Healthcare Providers & Services industry median of 10.21. GoodRx Holdings' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GoodRx Holdings (GDRX), the current EBITDA Margin % is 19.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GoodRx Holdings (GDRX) Overvalued in 2026?
Based on GuruFocus' analysis, GoodRx Holdings stock appears to be undervalued.
The current stock price of $2.69 is trading 52.5% below its estimated GF Value™ of $5.66.
GuruFocus considers GoodRx Holdings to be Possible Value Trap.
Key valuation signals for GDRX:
EBITDA Margin %: 19.17% (13% above median its 10-year median of 16.97)
GF Value™: $5.66 vs. price of $2.69 (52.5% below fair value)
Industry Position: 87.8% above the Healthcare Providers & Services median (#133 of 668)
No single metric tells the full story. See the GDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
60GF Score
Get the complete analysis for GDRX
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GDRX has been successfully added to your 
